NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for…
- Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory to salvage therapy - NEXI-001 is well tolerated with a favorable safety profile, including no…